Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Unscheduled healthcare interactions in multiple myeloma patients receiving T cell redirection therapies.
Howard AJ, Concepcion I, Wang AX, Hamadeh IS, Hultcrantz ML, Mailankody S, Tan CR, Korde N, Lesokhin AM, Hassoun H, Shah UA, Maclachlan KH, Rajeeve S, Landau HJ, Scordo M, Shah GL, Lahoud OB, Chung DJ, Giralt SA, Usmani SZ, Firestone RS. Howard AJ, et al. Among authors: shah ua. Blood Adv. 2024 Apr 12:bloodadvances.2024012871. doi: 10.1182/bloodadvances.2024012871. Online ahead of print. Blood Adv. 2024. PMID: 38621239
Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy.
Hamadeh IS, Shekarkhand T, Rueda CJ, Firestone RS, Wang AX, Korde N, Hultcrantz ML, Lesokhin AM, Mailankody S, Hassoun H, Shah UA, Maclachlan KH, Rajeeve S, Patel D, Shah GL, Scordo M, Lahoud OB, Chung DJ, Landau HJ, Giralt SA, Usmani SZ, Tan CR. Hamadeh IS, et al. Among authors: shah ua. Blood Adv. 2024 Apr 10:bloodadvances.2024012724. doi: 10.1182/bloodadvances.2024012724. Online ahead of print. Blood Adv. 2024. PMID: 38598713
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.
Ghobrial IM, Gormley N, Kumar SK, Mateos MV, Bergsagel PL, Chesi M, Dhodapkar MV, Dispenzieri A, Fonseca R, Getz G, Kastritis E, Kristinsson SY, Martinez-Climent JA, Manier S, Marinac CR, Maura F, Morgan GJ, Davies FE, Nadeem O, Nuvolone M, Paiva B, O'Donnell E, Prosper F, Shah UA, Sklavenitis-Pistofidis R, Sperling AS, Vassiliou GS, Munshi NC, Castle PE, Anderson KC, San Miguel JF. Ghobrial IM, et al. Among authors: shah ua. Blood Cancer Discov. 2024 May 1;5(3):146-152. doi: 10.1158/2643-3230.BCD-24-0022. Blood Cancer Discov. 2024. PMID: 38441243
Reversible No-Reflow Phenomenon in a Free Flap after 16 Hours.
Babu SR, Malhotra A, Shah UA, Dandekar PB, Chindarkar HP, Doddi AK, Chakraborty SS. Babu SR, et al. Among authors: shah ua. Indian J Plast Surg. 2023 Oct 6;56(6):552-554. doi: 10.1055/s-0043-1775553. eCollection 2023 Dec. Indian J Plast Surg. 2023. PMID: 38105877 Free PMC article. No abstract available.
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens.
Maura F, Boyle EM, Coffey D, Maclachlan K, Gagler D, Diamond B, Ghamlouch H, Blaney P, Ziccheddu B, Cirrincione A, Chojnacka M, Wang Y, Siegel A, Hoffman JE, Kazandjian D, Hassoun H, Guzman E, Mailankody S, Shah UA, Tan C, Hultcrantz M, Scordo M, Shah GL, Landau H, Chung DJ, Giralt S, Zhang Y, Arbini A, Gao Q, Roshal M, Dogan A, Lesokhin AM, Davies FE, Usmani SZ, Korde N, Morgan GJ, Landgren O. Maura F, et al. Among authors: shah ua. Nat Cancer. 2023 Dec;4(12):1660-1674. doi: 10.1038/s43018-023-00657-1. Epub 2023 Nov 9. Nat Cancer. 2023. PMID: 37945755
95 results